Department for Hematology and Oncology, University Children's Hospital, Tirsova 10, 11000 Belgrade, Serbia.
Med Oncol. 2010 Jun;27(2):449-53. doi: 10.1007/s12032-009-9232-x. Epub 2009 Jun 2.
Contemporary protocols ensure high-remission rate and long-term free survival in children with acute lymphoblastic leukemia (ALL), but small percentage of patients is still incurable. Molecular genetic methods helped to establish submicroscopic classification as well as minimal residual disease follow-up, considered to be responsible for relapse. Our study enrolled 70 pediatric patients with de novo ALL, analyzed using reverse transcriptase-polymerase chain reaction for the presence of four major risk-stratifying translocations (BCR/ABL, MLL/AF4, TEL/AML1, and E2A/PBX1). Bone marrow samples were collected at diagnosis, at the end of induction phase, and after intensive chemotherapy with the aim to establish the correlation between chromosomal aberration, clinical features, and treatment response. Presenting the results of this study, we offer another evidence of variable incidence and clinical characteristics of ALL subtypes.
当代方案可确保患有急性淋巴细胞白血病 (ALL) 的儿童达到高缓解率和长期无病生存,但仍有一小部分患者无法治愈。分子遗传学方法有助于建立亚微观分类和微小残留病随访,这被认为是导致复发的原因。我们的研究纳入了 70 名初诊 ALL 儿科患者,采用逆转录-聚合酶链反应分析四种主要的风险分层易位(BCR/ABL、MLL/AF4、TEL/AML1 和 E2A/PBX1)的存在情况。采集骨髓样本进行分析,包括诊断时、诱导期结束时和强化化疗后,旨在确定染色体异常、临床特征和治疗反应之间的关系。通过呈现这项研究的结果,我们提供了另一个证据,证明 ALL 亚型的发病率和临床特征存在差异。